Prostacyclin (PGIj) Is an anttthrombotic factor, which may prevent the initiation and the complications of arteriosclerosis. The most Important site of PGI 2 production Is the vascular endothellum, but little is known about how this process is regulated. In this connection, there Is special Interest In the roles of various growth factors released from platelets, macrophages, vascular smooth muscle cells, and the endothelial cells themselves. We investigated the effects of transforming growth factor-^ (TGF-/3), plateletderived growth factor (PDGF), and acidic and basic flbroblast growth factors (aFGF and bFGF) on the PGI 2 production of cultured human umbilical vein endothelial cells by measuring the stable metabolite of PGI 2 , 6-keto-prostaglandln F 1a) by radlolmmunoassay. TGF-0 Induced dose-and time-dependent stimulation of PGI 2 production. The lowest stimulatory concentration of TGF-/3 was 0.1 ng/ml, and the maximal response, a 2.1-fold rise, was obtained with 1.0 ng/ml. The effect of TGF-0 lasted 48 hours and was blocked by Inhibitors of transcription, translation, and cydooxygenase. Maximal stimulation by TGF-/3 was enhanced by epidermal growth factor. PDGF and bFGF had no effect on PGI 2 production, but aFGF Inhibited It This Is the first demonstration that TGF-0 enhances PGI 2 production by human vascular cells, and this phenomenon may be part of negative feedback mechanisms that prevent thrombosis and arteriosclerosis. (Arteriosclerosis 10:653-657, July/August 1990) P rostacyclin (PGy, a major arachidonic acid metabolite of vascular endothelial cells, is a powerful vasodilator and a potent inhibitor of platelet aggregation.
Recently, we showed that EGF, which is released from human platelets during aggregation, 12 and TGF-a, another ligand of the same receptor, 13 stimulate the in vitro production of PGI 2 in human umbilical vein endothelial cells. 1415 Thus these factors could prevent thrombosis and atherogenesis. To clarify further the role of growth factors, we studied the effects of TGF-/3, PDGF, acidic FGF (aFGF), and basic FGF (bFGF) on PGI 2 synthesis by human umbilical vein endothelial cells.
Methods Materials
Medium 199 and fetal calf serum were obtained from Flow Laboratories, Ayshire, U.K. Penicillin, streptomycin, and L-glutamine were purchased from GIBCO, Grand Island, NY. Collagenase CLS 3 was obtained from Worthington Biochemicals, Freehold, NJ. Gelatin was purchased from Merck, Darmstadt, F.R.G. Cycloheximide, actinomycin D, and mouse EGF were obtained from Sigma Chemical, St. Louis, MO. Indomethacin was purchased from Dumex, Copenhagen, Denmark. Porcine TGF-/31 was obtained from R&D Systems, Minneapolis, MN. PDGF and bFGF were purchased from AMGen, Thousand Oaks, CA. aFGF was obtained from Collaborative Research, Bedford, MA. All culture flasks and plates were purchased from Nunc, Roskilde, Denmark.
Endothelial Cell Cultures
Endothelial cell cultures were prepared from human umbilical cord veins with the approval of the local committee of ethics and according to the method originally described by Jaffe et al., 18 with slight modifications.
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Incubation Procedures
The effects of the growth factors on PGI 2 production were studied in 96-well plates by using confluent monolayers of endothelial cells after the first passage. Immediately before each experiment, the culture medium (Medium 199 supplemented with 20% fetal calf serum, 100 U/ml penicillin, 100 /ig/ml streptomycin, and 2 mM L-glutamine) was aspirated from the confluent monolayers, and these were washed once with 0.25 ml of culture medium. Fresh culture medium (0.25 ml) was added without (control) or with 0.01 to 10 ng/ml of TGF-/3 or 0.1 to 100 ng/ml of PDGF, bFGF, aFGF, or EGF. Cultures were incubated for 1 to 72 hours at 37°C in 5% CO 2 in air.
Cycloheximide (2 /ig/ml), actinomycin D (2 jig/ml), and indomethacin (1.4 fiM) were added simultaneously without (control) or with TGF-/3 (1.0 ng/ml) and incubated for 8 hours.
At the end of each incubation, the medium was placed in a polypropylene tube and was stored immediately at -20°C.
Analytical Methods
PGI 2 synthesis was measured by radioimmunoassay 17 of 6-keto-prostaglandin F 1a (6-keto-PGF 1a ), a stable metabolite of PGI 2 .
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Statistical Analysis
Statistical significance was calculated using Student's unpaired f test in the case of a single comparison. For multiple comparison, the f test was used only if one-way analysis of variance had shown a significant difference. All results are expressed as the means±SEM.
Results
TGF-/3 increased the release of 6-keto-PGF la in a dose-dependent manner. The lowest stimulatory concentration was 0.1 ng/ml, and the concentration giving the maximal (2.13±0.10-fold) response was 1.0 ng/ml (Figure 1) . The effect of TGF-/3 was time-dependent and increased progressively between 3 and 48 hours (Figure 2 ). After incubation for 3 hours, the increase was 1.47±0.17-fold (p<0.05) calculated from nine replicate determinations in three separate experiments, whereas incubation for 1 hour in the same experiments was ineffective. The maximal effect of TGF-0 was enhanced by 1 ng/ml of EGF, which by itself caused a 1.40±0.17-fold and together with TGF-0, a 3.51 ±0.06-fold increase in the release of 6-keto-PGF 1o ( Figure 3 ). PDGF, aFGF, and bFGF did not stimulate 6-keto-PGF 1o release ( Figure 1 ). In fact, aFGF was inhibitory at concentrations of 10 ng/ml ( Figure 1 ) and 100 ng/ml (not shown). The two concentrations of aFGF were equally potent.
Actinomycin D and cycloheximide blocked the stimulatory effect of TGF-/3, indicating that stimulation was dependent on de novo synthesis of RNA and protein, respectively (Table 1) . Indomethacin also inhibited the stimulatory effect of TGF-/3 and decreased the basal production of 6-keto-PGF 1a by 97%, confirming the key role of cyclooxygenase. 
Discussion
TGF-0 is a multifunctional peptide, which exerts either stimulatory or inhibitory effects on proliferation, differentiation, and other cell functions.
1920 TGF-0 prevents the growth of human vascular endothelial cells in vitro, 2122 but is angiogenic in mice in vivo. 20 The explanation of this may be that it is an attractant for macrophages and may stimulate the release of angiogenic peptides from them. TGF-/3 enhances the synthesis of endothelin 23 and plasminogen activator inhibitor type I, 24 elevates the expression of PDGF, 25 and inhibits the production of plasminogen activators in vascular endothelial cells. 24 Human platelets contain large amounts of TGF-0, 19 now known as TGF-01, 28 but macrophages and endothelial cells can also release it.
811 TGF-/3 is usually liberated from cultured cells as an inactive compound, 20 but plasmin can activate a small pool of this latent TGF-0. 27 However, in cocultures of endothelial and smooth muscle cells, TGF-0 is activated by plasmin, causing an inhibition of endothelial cell movement 28 Thus, sufficient amounts of active TGF-/3 may be present in the vascular wall and especially at a site of endothelial injury where platelets are aggregating to cause biologically important effects. The intracellular signaling mechanisms underlying the multiple actions of TGF-/3 remain essentially unknown. 20 Interestingly, it has been suggested that the antimitogenic effect of TGF-0 is dependent on de novo synthesis of prostaglandins. 29 The present data are the first demonstration that TGF-0 stimulates the synthesis of PG^ in any type of endothelial or human vascular cells. The magnitude of the stimulation by TGF-/3 was similar to what has been found for EGF, TGF-a, interteukin-1, and tumor necrosis factor-a. 14 ' 15 ' 3031 Thus TGF-A when released from platelets, macrophages, or endothelial cells, has an antithrombotic and antiatherogenic activity. Although PGI 2 is not itself angiogenic, 32 its stable analogues are, 33 and the increased production of PGI 2 may possibly contribute to maintaining the patency The values are the means±SEM of three replicate determinations and are given in ng/ml. The experiment was repeated twice with similar results.
Confluent monolayers of human umbilical vein endothelial cells were incubated for 8 hours without (control) or with TGF-0 (1.0 ng/ml) and/or with the indicated amounts of inhibitors. 6-keto-PGF 1a was measured by radloimmunoassay from conditioned medium.
*p<0.001 against the control. PGF, 0 =prostagtandin F la , TGF-0=transforming growth factor-/?.
of the developing vessel. Thus, stimulation of PGI 2 synthesis by TGF-/3 may also play a role in the angiogenic activity of TGF-£. The increase in PGI 2 production by endothelial cells depends on the synthesis of both RNA and protein.
Earlier it was shown that TGF-0 stimulated the synthesis of prostaglandin E 2 in an osteogenic cell line, and this effect was similarly dependent on synthesis of RNA and protein. 34 Thus the effect of TGF-0 is not prostanoid-or tissue-specific.
EGF potentiated the effect of TGF-/J in the stimulation of endothelial cell PGI 2 production. A similar effect has been reported in cultured rat smooth muscle cells, 35 in which TGF-0 and EGF synergistically accelerated the recovery of PGI 2 synthesis after aspirin treatment, which is associated with increased production of cyclooxygenase mRNA. 38 Unexpectedly, however, PGI 2 synthesis could not be inhibited by actinomycin D, but could be prevented by cycloheximide.
3638 Since TGF-/3 and EGF are both released from platelets, 1219 they are likely to act in concert at thrombotic sites. The combination of EGF and TGF-/3 may well be the platelet-derived stimulator of endothelial cell PGI 2 production implied by Tremoli et al. 37 aFGF and bFGF have an over 50% sequence homology and they act via the same high-affinity receptors that are also present in endothelial cells. 811 They are potent angiogenic factors and induce all the basic mechanisms of angiogenesis, which include increased protease release from the endothelium, and migration, proliferation, and tube formation by the endothelial cells. 811 bFGF is produced by macrophages and endothelial and smooth muscle cells, whereas aFGF is found mainly in neural tissue, 11 but to some extent also in vascular smooth muscle cells.
38 bFGF had no effect on endothelial PGI 2 synthesis, but aFGF inhibited it at the highest concentrations. This was somewhat unexpected, since bFGF is generally considered to be more potent than aFGF. However, aFGF was recently shown to inhibit the agonist-induced production of PGI 2 remains to be discovered whether PDGF stimulates the production of PGI 2 by capillary endothelial cells.
In conclusion, TGF-/3 may act as an antiatherogenic compound by increasing the production of endothelial PGI 2 , which prevents platelet aggregation, suppresses the proliferative capacity of smooth muscle cells, and decreases cholesterol accumulation in the vascular wall. The effect of TGF-/3 is potentiated by EGF.
